Patents Examined by Rayna B Rodriguez
-
Patent number: 9908884Abstract: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.Type: GrantFiled: May 5, 2010Date of Patent: March 6, 2018Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Pasi Janne, Michael J. Eck, Wenjun Zhou
-
Patent number: 9884809Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.Type: GrantFiled: October 8, 2015Date of Patent: February 6, 2018Assignee: REATA PHARMACEUTICALS, INC.Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
-
Patent number: 9884070Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: April 21, 2009Date of Patent: February 6, 2018Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of CaliforniaInventors: Sally J. Denardo, Gerald L. Denardo, Rodney L. Balhorn
-
Patent number: 9878980Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.Type: GrantFiled: October 28, 2016Date of Patent: January 30, 2018Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
-
Patent number: 9873682Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.Type: GrantFiled: April 19, 2017Date of Patent: January 23, 2018Assignee: GILEAD SCIENCES, INC.Inventor: Gregory Notte
-
Patent number: 9868729Abstract: Provided are methods of treating inflammatory disorders, autoimmune disorders, or a hematological malignancies using compounds of formula I and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof. Such disorders and conditions include leukemia and Non Hodgkin's Lymphoma.Type: GrantFiled: December 5, 2014Date of Patent: January 16, 2018Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Shawn M. Bauer, Anjali Pandey
-
Patent number: 9868696Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.Type: GrantFiled: December 28, 2015Date of Patent: January 16, 2018Assignee: Bezwada Biomedial, LLCInventor: Rao S Bezwada
-
Patent number: 9861598Abstract: A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.Type: GrantFiled: March 24, 2009Date of Patent: January 9, 2018Assignee: Teikoku Seiyaku Co., Ltd.Inventor: Masahiro Inazuki
-
Patent number: 9839665Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.Type: GrantFiled: February 11, 2016Date of Patent: December 12, 2017Assignee: Merck Patent GmbHInventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Birgitta Leuthner
-
Patent number: 9820935Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.Type: GrantFiled: March 10, 2016Date of Patent: November 21, 2017Assignee: EyeGate Pharmaceuticals, Inc.Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
-
Patent number: 9814724Abstract: The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; a method for inhibiting the growth of a tumor comprising the step of administering to a patient the aforementioned antitumor effect potentiator and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.Type: GrantFiled: February 17, 2017Date of Patent: November 14, 2017Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Junji Uchida, Koyo Shudo
-
Patent number: 9770024Abstract: A method for reducing parasites in aquatic animals is provided. The method includes administering to the aquatic animal a compound comprising propyl propane thiosulfonate (PTSO) having the formula R—SOa-S—R, where R represents n-propyl group (—CH2—CH2—CH3) and a is 2 and also propyl propane thiosulfinate (PTS) having the formula R—SOa-S—R, where R represents n-propyl group (—CH2—CH2—CH3) and a is 1, so that a combination of PTS and PTSO is administered to the aquatic animal resulting in the reduction of a plurality of crustaceans infecting the aquatic animal in response to administering the combination of PTS and PTSO to the aquatic animal.Type: GrantFiled: February 29, 2016Date of Patent: September 26, 2017Assignee: Investfood, LLCInventors: Cristina Núñez Lechado, Alberto Baños Arjona, Enrique Guillamón Ayala, Adela Valero López, Ma Concepción Navarro Moll, Ana Sanz Rus
-
Patent number: 9757350Abstract: Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 ?M. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC50 values below 3 ?M. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.Type: GrantFiled: January 16, 2015Date of Patent: September 12, 2017Assignees: Indiana University Research and Technology Corporation, Indiana State UniversityInventors: John J. Turchi, Richard Fitch
-
Patent number: 9750730Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.Type: GrantFiled: April 27, 2016Date of Patent: September 5, 2017Assignee: GILEAD SCIENCES, INC.Inventor: Gregory Notte
-
Patent number: 9744158Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.Type: GrantFiled: March 14, 2013Date of Patent: August 29, 2017Assignee: Ceva Sante AnimaleInventors: Anouck Lagarde, Stephane Floch, Thierry Bertaim
-
Patent number: 9737514Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.Type: GrantFiled: November 19, 2015Date of Patent: August 22, 2017Assignee: Children's Medical Center CorporationInventors: Joyce Bischoff, Shoshana Greenberger
-
Patent number: 9730923Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction of lactation, mammary involution, and for treating and/or intra-mammary diseases or infections of ruminants.Type: GrantFiled: April 7, 2011Date of Patent: August 15, 2017Assignee: Ceva Sante AnimaleInventors: Anouck Lagarde, Stephane Floch, Thierry Bertaim
-
Patent number: 9730943Abstract: The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 8, 2011Date of Patent: August 15, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: William Johnston Scott, Manfred Möwes, Ningshu Liu, Ursula Mönning, Ulf Bömer
-
Patent number: 9687496Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.Type: GrantFiled: February 19, 2015Date of Patent: June 27, 2017Assignee: ASARINA PHARMA ABInventors: Torbjörn Bäckström, Anders Carlsson
-
Patent number: 9676759Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: May 7, 2013Date of Patent: June 13, 2017Assignee: Vertex Pharmaceuticals IncorporatedInventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar